Transgene S.A. 2014 IR
The report outlines Transgene's financial and operational performance for the fiscal year 2014, highlighting a successful capital increase of ’65.5 million. The company focused on advancing its clinical pipeline, particularly its key immunotherapy candidates TG4010 for non-small cell lung cancer and Pexa-Vec for advanced liver cancer. Transgene also initiated clinical development for TG1050 targeting chronic hepatitis B. Additionally, the company commenced construction of a commercial-scale manufacturing platform in Lyon in partnership with Sanofi.
Company: Transgene S.A.
Sector: Professional & technical services
Country: France
Year: 2014
Type: IR
Pages: 172
Back to company
Transgene S.A.
Reference Document
The report outlines Transgene's financial and operational performance for the fiscal year 2014, highlighting a successful capital increase of ’65.5 million. The company focused on advancing its clinical pipeline, particularly its key immunotherapy candidates TG4010 for non-small cell lung cancer and Pexa-Vec for advanced liver cancer. Transgene also initiated clinical development for TG1050 targeting chronic hepatitis B. Additionally, the company commenced construction of a commercial-scale manufacturing platform in Lyon in partnership with Sanofi.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2014
Reporting Period
Jan 1, 2014 - Dec 31, 2014
Fiscal Year
2014
Published
Apr 28, 2015
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Water Consumption
Women on Board
Employees